ELISA/assay

Porcine Receptor for advanced glycatiom end products ELISA Kit

MBS751070

48-Strip-Wells

470 USD

ELISA Kit

Porcine Receptor for advanced glycatiom end products ELISA Kit

Receptor for advanced glycatiom end products

receptor for Advanced Glycation End Products; Advanced glycosylation end product-specific receptor; advanced glycosylation end product-specific receptor; RAGE isoform sRAGE-delta; RAGE isoform NtRAGE-delta; receptor for advanced glycation end-products variant 20; advanced glycosylation end product-specific receptor; Receptor for advanced glycosylation end products

RAGE

AGER; AGER; RAGE; RAGE

RAGE_HUMAN

Porcine

This assay has high sensitivity and excellent specificity for detection of RAGE. No significant cross-reactivity or interference between RAGE and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between RAGE and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This RAGE ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Porcine RAGE. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

. Principle of the assay: RAGE ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-RAGE antibody and an RAGE-HRP conjugate. The assay sample and buffer are incubated together with RAGE-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the RAGE concentration since RAGE from samples and RAGE-HRP conjugate compete for the anti-RAGE antibody binding site. Since the number of sites is limited, as more sites are occupied by RAGE from the sample, fewer sites are left to bind RAGE-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The RAGE concentration in each sample is interpolated from this standard curve.

4877291

CAB43108.1

Q15109

41,098 Da

AGE/RAGE Pathway (698754); Activated TLR4 Signalling Pathway (106400); Advanced Glycosylation Endproduct Receptor Signaling Pathway (187092); Cytosolic Sensors Of Pathogen-associated DNA Pathway (576255); DEx/H-box Helicases Activate Type I IFN And Inflammatory Cytokines Production Pathway (833822); Immune System Pathway (106386); Innate Immune System Pathway (106387); MyD88 Cascade Initiated On Plasma Membrane Pathway (205107); MyD88 Dependent Cascade Initiated On Endosome Pathway (187081); MyD88-independent Cascade Pathway (106401)

The advanced glycosylation end product (AGE) receptor encoded by this gene is a member of the immunoglobulin superfamily of cell surface receptors. It is a multiligand receptor, and besides AGE, interacts with other molecules implicated in homeostasis, development, and inflammation, and certain diseases, such as diabetes and Alzheimer's disease. Many alternatively spliced transcript variants encoding different isoforms, as well as non-protein-coding variants, have been described for this gene (PMID:18089847). [provided by RefSeq, May 2011]

RAGE: Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF- alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling. Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Interacts with S100B, S100A1 and APP. Interacts with S100A12. Endothelial cells. 4 isoforms of the human protein are produced by alternative splicing. Protein type: Receptor, misc.; Cell cycle regulation; Motility/polarity/chemotaxis; Membrane protein, integral. Chromosomal Location of Human Ortholog: 6p21.3. Cellular Component: integral to plasma membrane; extracellular region; plasma membrane. Molecular Function: identical protein binding; protein binding; transmembrane receptor activity; receptor activity. Biological Process: cell surface receptor linked signal transduction; response to wounding; innate immune response; inflammatory response; neurite development; activation of NF-kappaB transcription factor; induction of positive chemotaxis

48-Strip-Wells

470 USD

96-Strip-Wells

675